2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023 (584-588)
АУТОР(И) / AUTHOR(S): Milan Beljkas, Jelena Rebić, Milica Radan, Teodora Đikić, Slavica Oljačić, Katarina Nikolic
Е-АДРЕСА / E-MAIL: milan.beljkas@pharmacy.bg.ac.rs
DOI: 10.46793/ICCBI23.584B
САЖЕТАК / ABSTRACT:
Rho-associated coiled-coil kinases (ROCKs) are involved in essential cellular functions such as adhesion, contraction, motility, proliferation, and cell survival/apoptosis. Four ROCK inhibitors have already been approved by the FDA and are used to treat glaucoma (ripasudil and netarsudil), cerebral vasospasm (fasudil), and graft-versus-host disease (belumosudil). Recent studies have focused on exploring the role of ROCK kinase inhibitors in cancer treatment and the development of new ROCK inhibitors. The main objective of this study was to identify critical structural features relevant to the inhibition of ROCK1 using a ligand-based 3D-QSAR (3D quantitative structure-activity relationship) method. The 3D-QSAR model for ROCK1 was created and validated using internal and external validation parameters (R2, Q2, R2pred, rm 2, r/2m, rm̅̅2̅ and ∆r2m). The main structural features that correlate with the inhibition of ROCK1 were identified (e.g., heterocycle with hydrogen donor group like nitrogen atom) and further structural modifications of the ROCK1 inhibitors that contribute to increased activity were proposed (removal of the amino group of the oxadiazole, modification of the substituents of the phenyl ring).
КЉУЧНЕ РЕЧИ / KEYWORDS:
ROCK, cancer, 3D-QSAR, design
ЛИТЕРАТУРА / REFERENCES:
- Julian L, Olson M F (2014) Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions, Small GTPases. 5(2), e29846.
- Amano M, Nakayama M, Kaibuchi K (2010) Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton, 67(9), 545–554.
- Hahmann C, Schroeter T (2009). Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cellular and Molecular Life Sciences, 67(2), 171–177
- Barcelo, J., Samain, R., & Sanz-Moreno, V. (2023). Preclinical to clinical utility of ROCK inhibitors in cancer. Trends in Cancer
- Bandarage U, Hare B, Parsons J, Pham L, Marhefka C, Bemis G, … Green J (2009) 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters, 19(17), 5191–5194
- Green J, Cao J, Bandarage U K, Gao H, Court J, Marhefka C, … Rodems S (2015) Design, Synthesis, and Structure–Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors. Journal of Medicinal Chemistry, 58(12), 5028–5037
- Frisch, M. J. (1998). Gaussian 98 (RevisionA.7). Pittsburgh, PA: Gaussian, Inc.
- Pastor M, Cruciani G, McLay I, Pickett S, Clementi S (2000) Grid-INdependent Descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors. Journal of Medicinal Chemistry, 43(17), 3233–3243.
- Pentacle,Version1.0.6,MolecularDiscoveryLtd.,Perugia,Italy;2009
- Ojha P K, Roy K (2011) Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection. Chemometrics and Intelligent Laborary Systems., 109(2), 146–161
- Tropsha, A. (2010). Best practices for QSAR model development, validation, and exploitation. Molecular Informatics, 29(6-7), 476–488
- Roy P P, Roy K (2008) On some aspects of variable selection for partial least squares regression models. QSAR & Combinatorial Science, 27(3), 302–313.